Radiopharm - Model DUNP19 - Radioactive Drugs

DUNP19 is the invention of Professor Ulmert at UCLA.

• DUNP19 "dual action LRRC15 targeting antibody" is a first-in-class small antibody, that has a unique ability to target both tumour and the surrounding tumour micro-environment ("TME") cells, such as stromal and immune cells which comprise more than 50% of tumour masses.  Currently available antibodies for cancer treatment generally fail to target TME cells.  
• Applicable to a broad range of currently untreatable cancers.
• initial indication will be osteosarcoma, a type of bone cancer that primarily targets children, adolescents and young adults.  Osteosarcoma expresses high levels of LRRC15, making it an ideal target for this antibody.
• In September 2022 the FDA granted Orphan Drug Designation and Pediatric Rare Disease designation to DUNP19 in osteosarcoma.

PRECLINICAL DATAHumanized Monoclonal Antibody DUNP19